The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

Author:

Liu Bingru12,Lu Yu123ORCID,Taledaohan Ayijiang12,Qiao Shi4,Li Qingyan4,Wang Yuji123ORCID

Affiliation:

1. Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China

2. Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China

3. Department of Core Facility Center, Capital Medical University, Beijing 100069, China

4. Civil Aviation Medical Center, Civil Aviation Administration of China, Beijing 100123, China

Abstract

Increased glycolysis is a key characteristic of malignant cells that contributes to their high proliferation rates and ability to develop drug resistance. The glycolysis rate-limiting enzyme hexokinase II (HK II) is overexpressed in most tumor cells and significantly affects tumor development. This paper examines the structure of HK II and the specific biological factors that influence its role in tumor development, as well as the potential of HK II inhibitors in antitumor therapy. Furthermore, we identify and discuss the inhibitors of HK II that have been reported in the literature.

Funder

Beijing Municipal Colleges and Universities High-Level Talents Introduction and Cultivate Project-Beijing Great Wall Scholar Program

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Reference193 articles.

1. Cancer statistics in China, 2016;Zheng;Zhonghua Zhong Liu Za Zhi,2023

2. Cancer statistics;Siegel;CA Cancer J. Clin.,2023

3. Dual or multi-targeting inhibitors: The next generation anticancer agents;Raghavendra;Eur. J. Med. Chem.,2018

4. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm;Fu;Eur. J. Med. Chem.,2017

5. Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship;Singh;Anti-Cancer Agents Med. Chem.,2019

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3